Sign In
Buy SRTA
Strata Critical Medical Earnings Calls
| Release date | Aug 04, 2026 |
| EPS estimate | -$0.0400 |
| EPS actual | - |
| Revenue estimate | 66.988M |
| Revenue actual | - |
| Expected change | +/- 10.11% |
| Release date | May 06, 2026 |
| EPS estimate | -$0.0400 |
| EPS actual | $0.0300 |
| EPS Surprise | 175.00% |
| Revenue estimate | 63.675M |
| Revenue actual | 67.384M |
| Revenue Surprise | 5.82% |
| Release date | Mar 03, 2026 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0621 |
| EPS Surprise | -721.40% |
| Revenue estimate | 60.35M |
| Revenue actual | 66.787M |
| Revenue Surprise | 10.67% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0600 |
| EPS Surprise | -200.00% |
| Revenue estimate | 60.35M |
| Revenue actual | 49.298M |
| Revenue Surprise | -18.31% |
Last 4 Quarters for Strata Critical Medical
Below you can see how SRTA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 10, 2025 |
| Price on release | $4.85 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0600 |
| EPS surprise | -200.00% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $4.72 |
| Nov 05, 2025 | $4.62 |
| Nov 06, 2025 | $4.65 |
| Nov 07, 2025 | $4.43 |
| Nov 10, 2025 | $4.85 |
| Nov 11, 2025 | $5.04 |
| Nov 12, 2025 | $5.10 |
| Nov 13, 2025 | $4.89 |
| Nov 14, 2025 | $4.79 |
| 4 days before | 2.75% |
| 4 days after | -1.24% |
| On release day | 3.92% |
| Change in period | 1.48% |
| Release date | Mar 03, 2026 |
| Price on release | $4.80 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0621 |
| EPS surprise | -721.40% |
| Date | Price |
|---|---|
| Feb 25, 2026 | $4.26 |
| Feb 26, 2026 | $4.43 |
| Feb 27, 2026 | $4.28 |
| Mar 02, 2026 | $4.49 |
| Mar 03, 2026 | $4.80 |
| Mar 04, 2026 | $4.89 |
| Mar 05, 2026 | $4.75 |
| Mar 06, 2026 | $4.54 |
| Mar 09, 2026 | $4.57 |
| 4 days before | 12.68% |
| 4 days after | -4.79% |
| On release day | 1.88% |
| Change in period | 7.28% |
| Release date | May 06, 2026 |
| Price on release | $5.33 |
| EPS estimate | -$0.0400 |
| EPS actual | $0.0300 |
| EPS surprise | 175.00% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $5.02 |
| May 01, 2026 | $5.08 |
| May 04, 2026 | $4.90 |
| May 05, 2026 | $4.82 |
| May 06, 2026 | $5.33 |
| May 07, 2026 | $5.34 |
| May 08, 2026 | $5.57 |
| May 11, 2026 | $5.66 |
| May 12, 2026 | $5.47 |
| 4 days before | 6.18% |
| 4 days after | 2.63% |
| On release day | 0.188% |
| Change in period | 8.96% |
| Release date | Aug 04, 2026 |
| Price on release | - |
| EPS estimate | -$0.0400 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jun 09, 2026 | $5.61 |
| Jun 10, 2026 | $5.48 |
| Jun 11, 2026 | $5.49 |
| Jun 12, 2026 | $5.43 |
| Jun 15, 2026 | $5.89 |
Strata Critical Medical Earnings Call Transcript Summary of Q1 2026
Strata reported a strong Q1 2026 with total revenue of $67.4M, up 87% year-over-year, driven by 32% organic growth in Logistics and rapid contribution from the Clinical business added via Keystone. The company generated operating cash flow and free cash flow (before aircraft acquisitions) for the first time since its transformation and reiterated full-year 2026 guidance: revenue $260M–$275M, adjusted EBITDA $29M–$33M, and free cash flow before aircraft/engine purchases $15M–$22M. Logistics growth was slightly soft sequentially due to customer mix (shorter trip distances) and weather-related airport closures, while Clinical revenue and gross margins strengthened, driven by NRP and third-party Surgical Recovery wins and new customer onboarding. Management announced a small tuck-in acquisition (Ohio Valley Perfusion Associates) and emphasized an active M&A pipeline targeting fragmented, strategically complementary businesses. Balance sheet liquidity remains robust (~$59M cash, undrawn $30M ABL, potential ~$45M earn-out from Passenger divestiture), and the company expects Logistics gross margins to stay around the low-20% range for the year (impacted by fuel surcharges and mix). Management highlighted industry trends—growing adoption of NRP, third-party recovery and machine perfusion—creating structural growth opportunities and a shortage of in-house recovery surgeon capacity, which favors Strata’s integrated logistics-plus-clinical model.
